EMA/324334/2024

European Medicines Agency decision

P/0246/2024

of 18 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for donidalorsen, (EMEA-003112-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0246/2024

of 18 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for donidalorsen, (EMEA-003112-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0274/2022 issued on 10 August 2022,

Having regard to the application submitted by Otsuka Pharmaceutical Netherlands B.V. on 25 March 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for donidalorsen, solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT – Amsterdam, The Netherlands.

EMA/PDCO/145838/2024
Amsterdam, 28 June 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-003112-PIP01-21-M01

Scope of the application

Active substance(s):

Donidalorsen

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hereditary angioedema

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Otsuka Pharmaceutical Netherlands B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Otsuka Pharmaceutical Netherlands B.V. submitted to the European Medicines Agency on 25 March 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0274/2022 issued on 10 August 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 29 April 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hereditary angioedema

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of hereditary angioedema

2.1.1. Indication(s) targeted by the PIP

Routine prevention of recurrent attacks of hereditary angioedema in patients aged 2 years and older

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	**Study 1** Definitive juvenile toxicity study in mice
Clinical studies	**Study 2 - ISIS 721744-CS5** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of donidalorsen in adolescents from 12 years to less than 18 years of age (and adults) with hereditary angioedema (HAE) **Study 3 - ISIS 721744 CS7** Open-label, follow-up trial to evaluate long-term safety and efficacy of donidalorsen in adolescents from 12 years to less than 18 years of age (and adults) with hereditary angioedema (HAE)

	Study 4 - ISIS 721744-CS8 Open-label, uncontrolled trial to evaluate safety, activity and pharmacokinetics (PK) of donidalorsen in children from 2 years to less than 12 years of age with hereditary angioedema (HAE)
Extrapolation, modelling and simulation studies	**Study 5** Modelling and simulation study to evaluate the use of donidalorsen in children from 2 years to less than 12 years of age with hereditary angioedema (HAE)
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.